- Email: [email protected]
Aquarion establishes joint venture in Asia
NEWS For further information, visit www.aquarion-group.com
PCI Membranes buys Pentair product line
P
CI Membranes has completed the strategic acquisition of Pentair’s X-Flow Classic Tubular Membrane, including assets and customers. The ‘Classic Membranes’ tubular membrane product is suited to handling aqueous feeds with high levels of dry substances (up to 40 000 ppm), high viscosities, or high degrees of fouling. “This agreement with industry leader Pentair demonstrates our global leadership in advanced filtration solutions,” said Ian Sadler, managing director of PCI Membranes. “We are excited to utilize this new product offering to solve more problems for our customers and increase the quality and efficiency that we are known for.” PCI Membranes, which is part of the Filtration Group, says it will restructure its manufacturing lines to incorporate the product line. “Our strong portfolio of intellectual property, combined with our large network of expertise in advanced filtration, puts us into unique strata within our arena,” said Sadler, “and this is just the next step in our continued innovation roadmap.”
For further information, visit www.pcimembranes.com/ en-US, www.pentair.com and www.filtrationgroup.com
Aquarion establishes joint venture in Asia
A
quarion Group has announced a new cooperation in Asia. H+E Darcarion Pte Ltd, a Singapore joint venture, will hold 100% of H+E Asia (Aquarion Group’s South East Asian entity) and will operate with the full technical and managerial support of H+E GmbH based in Stuttgart, Germany. Dr Karl Michael Millauer, CEO of Aquarion AG, said: “This is a significant milestone in Aquarion’s strategy in Asia and I look forward to working with the JV partners who will provide excellent local expertise.” Aquarion Group provides advanced water systems, solutions and technologies for the oil & gas industry, the energy sector and other process industries. The company has operations in Germany, Switzerland, Austria, Italy, the UK, the UAE, Chile, Russia, Southeast Asia and Australia. 14
Filtration Industry Analyst
Pall named singlesource supplier for French bio facility
P
harmaceutical company Servier has selected Pall Corp as an exclusive technology and services provider for its biomanufacturing facility in Gidy, France. Pall Biotech end-to-end solutions will be used for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins, resulting in increased speed to market and reduced customer costs. The facility is part of Servier’s Bio-S project which is focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale. The Bio-S project at the Gidy facility includes production lines to support internal production needs with up to 2000L bioreactor capacity that can be run in a parallel format. The Bio-S unit aligns various activities, including a development workshop dedicated to monoclonal antibody processes (bio-engineering) which will be operational by 2019. The rest of the unit will be operational in 2020. “We are honoured to have been chosen and look forward to delivering comprehensive and scalable biomanufacturing solutions from upstream to downstream and through to fill and finish, as well as process development service expertise,” said Ed Hoare, vice president & general manager at Pall Biotech. “We have dedicated a great deal of resources to become more than just a supplier and will act as a co-development partner for all customer production steps.” “The Bio-S project in Gidy is the beginning of an industrial solution for biomanufacturing in France, offering an innovative path for critical oncology therapies, one of the main strategic priorities for Servier,” said Renaud Bessière, director of the Bio-S Project at Servier. “We selected Pall Biotech as our single supplier because of their capacity to deliver the complete suite of development and manufacturing equipment, including an automation package, assurance of consumables supply and technical support under a well-defined project execution plan.”
For further information, visit www.biotech.pall.com, www.pall.com and www.servier.com
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) Limited 12976 The content of this newsletter is compiled from a variety of sources including press releases.
July 2019
PCI Membranes buys Pentair product line
P
CI Membranes has completed the strategic acquisition of Pentair’s X-Flow Classic Tubular Membrane, including assets and customers. The ‘Classic Membranes’ tubular membrane product is suited to handling aqueous feeds with high levels of dry substances (up to 40 000 ppm), high viscosities, or high degrees of fouling. “This agreement with industry leader Pentair demonstrates our global leadership in advanced filtration solutions,” said Ian Sadler, managing director of PCI Membranes. “We are excited to utilize this new product offering to solve more problems for our customers and increase the quality and efficiency that we are known for.” PCI Membranes, which is part of the Filtration Group, says it will restructure its manufacturing lines to incorporate the product line. “Our strong portfolio of intellectual property, combined with our large network of expertise in advanced filtration, puts us into unique strata within our arena,” said Sadler, “and this is just the next step in our continued innovation roadmap.”
For further information, visit www.pcimembranes.com/ en-US, www.pentair.com and www.filtrationgroup.com
Aquarion establishes joint venture in Asia
A
quarion Group has announced a new cooperation in Asia. H+E Darcarion Pte Ltd, a Singapore joint venture, will hold 100% of H+E Asia (Aquarion Group’s South East Asian entity) and will operate with the full technical and managerial support of H+E GmbH based in Stuttgart, Germany. Dr Karl Michael Millauer, CEO of Aquarion AG, said: “This is a significant milestone in Aquarion’s strategy in Asia and I look forward to working with the JV partners who will provide excellent local expertise.” Aquarion Group provides advanced water systems, solutions and technologies for the oil & gas industry, the energy sector and other process industries. The company has operations in Germany, Switzerland, Austria, Italy, the UK, the UAE, Chile, Russia, Southeast Asia and Australia. 14
Filtration Industry Analyst
Pall named singlesource supplier for French bio facility
P
harmaceutical company Servier has selected Pall Corp as an exclusive technology and services provider for its biomanufacturing facility in Gidy, France. Pall Biotech end-to-end solutions will be used for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins, resulting in increased speed to market and reduced customer costs. The facility is part of Servier’s Bio-S project which is focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale. The Bio-S project at the Gidy facility includes production lines to support internal production needs with up to 2000L bioreactor capacity that can be run in a parallel format. The Bio-S unit aligns various activities, including a development workshop dedicated to monoclonal antibody processes (bio-engineering) which will be operational by 2019. The rest of the unit will be operational in 2020. “We are honoured to have been chosen and look forward to delivering comprehensive and scalable biomanufacturing solutions from upstream to downstream and through to fill and finish, as well as process development service expertise,” said Ed Hoare, vice president & general manager at Pall Biotech. “We have dedicated a great deal of resources to become more than just a supplier and will act as a co-development partner for all customer production steps.” “The Bio-S project in Gidy is the beginning of an industrial solution for biomanufacturing in France, offering an innovative path for critical oncology therapies, one of the main strategic priorities for Servier,” said Renaud Bessière, director of the Bio-S Project at Servier. “We selected Pall Biotech as our single supplier because of their capacity to deliver the complete suite of development and manufacturing equipment, including an automation package, assurance of consumables supply and technical support under a well-defined project execution plan.”
For further information, visit www.biotech.pall.com, www.pall.com and www.servier.com
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) Limited 12976 The content of this newsletter is compiled from a variety of sources including press releases.
July 2019